Sugi Predict

Sugi Predict / Compounds / SCHEMBL796852

SCHEMBL796852

SCHEMBL796852

COC(=O)c1ccc(C(C)O)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ S1PR4 O95977 1/20 0.47
▸ S1PR3 Q99500 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ CA1 P00915 2/20 0.44
▸ CA2 P00918 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ RAB9A P51151 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ MAPT P10636 4/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.43
▸ CYP4F2 P78329 1/20 0.42
▸ CYP4A11 Q02928 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL179293 0.88 MAPK1 (0.61) MAPK1KDM4EL3MBTL1S1PR4S1PR3
SCHEMBL22060648 0.87 MAPK1 (0.60) MAPK1KDM4EL3MBTL1S1PR4S1PR3
SCHEMBL3645881 0.85 MAPK1 (0.57) MAPK1KDM4EL3MBTL1S1PR4S1PR3
SCHEMBL7419598 0.85 MAPK1 (0.57) MAPK1KDM4EL3MBTL1S1PR4S1PR3
SCHEMBL3645879 0.85 MAPK1 (0.57) MAPK1KDM4EL3MBTL1S1PR4S1PR3
SCHEMBL13418633 0.85 MAPK1 (0.57) MAPK1KDM4EL3MBTL1S1PR4S1PR3
SCHEMBL28230930 0.85 MAPK1 (0.57) MAPK1KDM4EL3MBTL1S1PR4S1PR3
Hydrochloric Acid SCHEMBL29893688 0.83 MAPK1 (0.56) MAPK1KDM4EL3MBTL1S1PR4S1PR3
Hydrochloric Acid SCHEMBL28240714 0.83 MAPK1 (0.56) MAPK1KDM4EL3MBTL1S1PR4S1PR3
Hydrochloric Acid SCHEMBL28240715 0.83 MAPK1 (0.56) MAPK1KDM4EL3MBTL1S1PR4S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN BIOTECH, INC. 2024-08-22 — — US disclosed
CN-118515675-A Alpha 5-GABAAReceptor modulators and uses thereof 武汉人福创新药物研发中心有限公司 2024-08-20 — — CN disclosed
CN-117881661-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-04-12 — — CN disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 — — US disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 — — US disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 — — US disclosed
EP-4192830-A1 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY Italfarmaco SpA (IT) 2023-06-14 — — EP disclosed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 — — CN disclosed
WO-2022253255-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 — — WO disclosed
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 — — EP disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 — — US disclosed
EP-2655331-A1 GLUCAGON RECEPTOR MODULATORS Pfizer Inc (US) 2013-10-30 — — EP disclosed
EP-2616465-A1 TRIAZINE-OXADIAZOLES Novartis AG (CH) 2013-07-24 — — EP disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 — — US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 — — WO disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 — — US disclosed
US-20120165343-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2012-06-28 — — US disclosed
WO-2012085745-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2012-06-28 — — WO disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 — — WO disclosed
US-20090221611-A1 Fused Triazole Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 MAPK1 2380/4885KDM4E 562/4885L3MBTL1 1844/4885
US-20120165343-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 MAPK1 239/4885KDM4E 3943/4885L3MBTL1 1602/4885
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 MAPK1 4056/4885KDM4E 3515/4885L3MBTL1 4523/4885
US-20140051676-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 MAPK1 3234/4885KDM4E 3067/4885L3MBTL1 4747/4885
US-20090221611-A1 Fused Triazole Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 MAPK1 1477/4885KDM4E 3697/4885L3MBTL1 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.